Pharmaceutical

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the…

4 days ago

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk…

4 days ago

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance…

4 days ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ASC Inhibitor IC 100…

4 days ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic   SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.…

4 days ago

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…

4 days ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1…

4 days ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials…

4 days ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform…

4 days ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel…

4 days ago